JDRF T1D Fund invests in glucose sensor co GluSense

biomed

The Israeli company is developing a long lasting injectable glucose sensor for treatment of Type 1 diabetes.

Israeli medical device company GluSense has received an investment from the JDRF T1D Fund. Rehovot based GluSense is developing a long lasting injectable glucose sensor for treatment of Type 1 diabetes. The amount of the investment was not disclosed.

Founded in 2007 GluSense is part of the Rainbow Medical innovation house, a unique private business that seeds and grows companies developing breakthrough medical devices. GluSense's Glyde CGM is a miniature long term injectable glucose sensor. It is injected under the skin and is expected to last for one year, providing continuous, accurate glucose measurements wirelessly to a convenient wearable device such as a watch. The injection of the device is minimally invasive and can be performed in a clinic using only local anesthesia. The T1D Fund's investment will be used to bring the Glyde CGM closer to the first in-human clinical trial, a key step in the commercialization process.

GluSense CEO Dr. Boaz Brill said, "Today, diabetic patients need to endure frequent finger pricks daily in order to manage their glucose level, and even with modern CGMs, frequent calibrations, measurement verifications and replacements are still a hassle and limit efficient treatment. In contrast, our Glyde continuous glucose monitor (CGM) will provide accurate glucose measurement for a full year with significantly fewer blood glucose calibrations. This ground-breaking technology will simplify and improve the life of people living with T1D and insulin dependent T2D worldwide."

"This collaboration is a significant recognition of the GluSense product and technology," said Efi Cohen-Arazi, Chairman of GluSense and CEO of Rainbow Medical. "It will speed up our development process and ensure the technology meets the needs of patients and caregivers."

"The GluSense Glyde CGM is a highly innovative and promising technology," said Jonathan Behr, Managing Director of the T1D Fund. "When paired with future advanced artificial pancreas systems or insulin injections, it will reduce the burden of T1D and help those living with the disease maintain blood glucose levels in a safe range."

GluSense's technology uses a proprietary fluorescent glucose-sensitive biosensor that ensures accurate glucose measurement across the full physiological range, with enhanced accuracy at the medically-important hypo glucose range. Another GluSense breakthrough ensures that the biosensor level in the implant is maintained stable over the long term using engineered live cells that constantly replenish the biosensor in the implant. The stable biosensor level enables calibration frequency to be significantly reduced, freeing users from the daily hassle of multiple calibration finger pricks.

Published by Globes [online], Israel business news - www.globes-online.com - on February 16, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018